Summit Therapeutics (SMMT) Expected to Announce Earnings on Monday

Key Points

• Summit Therapeutics is expected to announce its Q3 2025 earnings on October 20th, with analysts predicting a loss of ($0.15) per share and revenues of $77.16 million.
• Currently, Summit Therapeutics' shares are trading at $22.48, reflecting a 0.7% decline, with the stock's 12-month high reaching $36.91.
• Recent ratings from analysts show a consensus "Moderate Buy" with an average target price of $31.29, and a majority of analysts have rated the stock with a buy or hold recommendation.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) will likely be releasing its Q3 2025 results before the market opens on Monday, October 20th. Analysts expect Summit Therapeutics to post earnings of ($0.15) per share and revenue of $77.1570 million for the quarter. Interested persons may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, October 20, 2025 at 8:00 AM ET.

Summit Therapeutics (NASDAQ:SMMT - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.66). On average, analysts expect Summit Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Summit Therapeutics Stock Down 0.7%

Shares of NASDAQ SMMT traded down $0.17 during trading on Thursday, reaching $22.48. 1,444,276 shares of the stock were exchanged, compared to its average volume of 3,762,692. The business's 50-day moving average price is $22.75 and its 200 day moving average price is $23.32. Summit Therapeutics has a twelve month low of $15.55 and a twelve month high of $36.91. The company has a market capitalization of $16.70 billion, a price-to-earnings ratio of -22.28 and a beta of -1.13.

Analysts Set New Price Targets

A number of research analysts have recently commented on SMMT shares. JMP Securities reissued a "market outperform" rating and set a $40.00 target price on shares of Summit Therapeutics in a research report on Wednesday, September 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Summit Therapeutics in a research report on Wednesday, October 8th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Summit Therapeutics in a research note on Tuesday, September 16th. Piper Sandler initiated coverage on shares of Summit Therapeutics in a research note on Monday, August 18th. They issued a "neutral" rating and a $21.00 price target for the company. Finally, Evercore ISI lifted their price target on shares of Summit Therapeutics from $30.00 to $34.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 12th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and four have given a Sell rating to the company. According to data from MarketBeat.com, Summit Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $31.29.

Insider Buying and Selling at Summit Therapeutics

In other news, CEO Mahkam Zanganeh purchased 5,000 shares of Summit Therapeutics stock in a transaction dated Thursday, September 11th. The stock was bought at an average price of $18.07 per share, with a total value of $90,350.00. Following the completion of the acquisition, the chief executive officer owned 556,093,090 shares in the company, valued at $10,048,602,136.30. The trade was a 0.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert W. Duggan purchased 5,000 shares of Summit Therapeutics stock in a transaction dated Thursday, September 11th. The shares were purchased at an average cost of $18.07 per share, with a total value of $90,350.00. Following the acquisition, the chief executive officer owned 556,093,090 shares of the company's stock, valued at approximately $10,048,602,136.30. This trade represents a 0.00% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 676,788 shares of company stock valued at $11,969,512. 84.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Summit Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Quantbot Technologies LP acquired a new stake in Summit Therapeutics in the second quarter worth about $132,000. California State Teachers Retirement System lifted its holdings in Summit Therapeutics by 62.3% in the second quarter. California State Teachers Retirement System now owns 7,368 shares of the company's stock worth $157,000 after purchasing an additional 2,828 shares during the period. Jump Financial LLC acquired a new stake in Summit Therapeutics in the second quarter worth about $244,000. Oxford Asset Management LLP acquired a new stake in Summit Therapeutics in the second quarter worth about $245,000. Finally, Raymond James Financial Inc. acquired a new stake in Summit Therapeutics in the second quarter worth about $249,000. Institutional investors and hedge funds own 4.61% of the company's stock.

Summit Therapeutics Company Profile

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.